JP2000511519A - 生物学的製品の最終滅菌法 - Google Patents
生物学的製品の最終滅菌法Info
- Publication number
- JP2000511519A JP2000511519A JP09540666A JP54066697A JP2000511519A JP 2000511519 A JP2000511519 A JP 2000511519A JP 09540666 A JP09540666 A JP 09540666A JP 54066697 A JP54066697 A JP 54066697A JP 2000511519 A JP2000511519 A JP 2000511519A
- Authority
- JP
- Japan
- Prior art keywords
- group
- product
- composition
- virus
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.生物学的に活性な製品の無菌的投与のための最終殺菌方法において, (a)製品とその製品を実質的に熱安定性にするのに十分な量のα−D−グル コピラノシル-α-D-グルコピラノシド(トレハロース)を含む乾燥サンプルを 取得する工程および, (b)乾燥サンプルを感染性ウイルスを実質的に不活性化するのに十分な温度 および時間加熱する工程を含む方法. 2.製品は血液に由来し,アルブミン製品,免疫グロブリン,凝固製品および プロテアーゼ阻害剤からなる群より選択される「請求項1」記載の方法. 3.アルブミン製品はHSA,寒冷可溶性グロブリンおよびフィブリノーゲン からなる群より選択される「請求項2」記載の方法. 4.免疫グロブリンは破傷風,百日咳,肝炎,ヘルペス,水痘帯状庖疹,レン チウイルスおよび狂犬病に対する抗体からなる群より選択される「請求項2」記 載の方法. 5.凝固製品は抗血友病VIII因子,IX因子複合体および活性化IX因子複合体か らなる群より選択される「請求項2」記載の方法. 6.プロテアーゼ阻害剤はα−1プロテアーゼ阻害剤および抗トロンビンIII からなる群より選択される「請求項2」記載の方法. 7.生物学的に活性な製品は,全血,血漿,血清,胎盤,乳汁,尿,細胞培養 物および細胞培養液上清からなる群より選択される生物学的起源から得られる「 請求項1」記載の方法. 8.生物学的起源は細胞培養物または細胞培養液上清であり,製品はコロニー 刺激因子,モノクローナル抗体およびそれらの誘導体,ならびに増殖因子からな る群より選択される「請求項7」記載の方法. 9.生物学的起源は細胞培養物または細胞培養液上清であり,製品は組換え体 である「請求項7」記載の方法. 10.増殖因子はエリトロポエチン,サイトカインおよびインターロイキンから なる群より選択される「請求項7」記載の方法. 11.生物学的に活性な製品は鎮痛剤である「請求項1」記載の方法. 12.鎮痛剤はモルヒネ,ベンゾカイン,ペチジンおよびデメロールからなる群 より選択される「請求項11記載の方法. 13.生物学的に活性な製品は麻酔剤である「請求項1」記載の方法. 14.麻酔剤はブピビカイン,アトラキュリウムおよびべキュロニウムからなる 群より選択される「請求項13」記載の方法. 15.生物学的に活性な製品は化学療法剤である「請求項1」記載の方法. 16.化学療法剤は放射性同位元素,ビンカアルカロイド,アドリアマイシン, 硫酸ブレオマイシン,カルボプラチン,シスプラチン,シクロホスファミド,シ タラビン,ダカルバジン.ダクチノマイシン,塩酸ドゥアノルビシン,塩酸ドキ ソルビシン,エトポシド,フルオロウラシル,塩酸メクロロレタミン,メルファ ラン,メルカプトプリン,メトトレキセート,マイトマイシン,マイトタン,ペ ントスタチン,ピポブロマン,塩酸プロカルベーズ,ストレプトゾトシン,タキ ソール,チオグアニン,ならびにウラシルマスタードからなる群より選択される 「請求項15」記載の方法. 17.生物学的に活性な製品はホルモンである「請求項1」記載の方法. 18.ホルモンはエストロジェン,テストステロン,プロゲステロンおよびそれ らの合成同族体からなる群より選択される「請求項17」記載の方法. 19.生物学的に活性な製品はワクチンである「請求項1」記載の方法. 20.ワクチンは,単一および多重抗原サブユニットワクチン,死菌およびウイ ルスプレパレーションならびに癌抗原からなる群より選択される「請求項19」記 載の方法. 21.乾燥サンプルは空気乾燥,真空乾燥,スプレー乾燥および凍結乾燥からな る群より選択される方法によって得られる「請求項1」記載の方法. 22.実質的な熱安定性は製品の活性の約30%未満の喪失を生じる「請求項1」 記載の方法. 23.安定性は製品活性の約15%未満の喪失を生じる「請求項22」記載の方法. 24.安定性は製品活性の約10%未満の喪失を生じる「請求項23」記載の方法. 25.乾燥したサンプルの残留水分含量は約4%未満である「請求項1」記載の 方法. 26.残留水分含量は約2%未満である「請求項25」記載の方法. 27.残留水分含量は約1%未満である「請求項26」記載の方法. 28.加熱温度は約80℃であって,加熱の持続時間は少なくとも約72時間である 「請求項1」記載の方法. 29.加熱温度は約90℃であって,加熱の持続時間は少なくとも約20時間である 「請求項1」記載の方法. 30.感染ウイルスの実質的な不活性化はウイルスの感染性の104倍の低下を生 じる「請求項1」記載の方法. 31.不活性化は脂質エンベロープをもたないウイルスの感染性の104倍の低下 を生じる「請求項1」記載の方法. 32.脂質エンベロープをもたないウイルスはA型肝炎ウイルスおよびパルボウ イルスからなる群より選択される「請求項1」記載の方法. 33.脂質エンベロープをもたないウイルスは,パルボウイルスである「請求項 32」記載の方法. 34.「請求項1」記載の方法によって得られる組成物. 35.製品は血液に由来し,アルブミン製品,免疫グロブリン,凝固製品および プロテアーゼ阻害剤からなる群より選択される「請求項34」記載の組成物. 36.アルブミン製品はHSA,寒冷可溶性グロブリンおよびフィブリノーゲン からなる群より選択される「請求項35」記載の組成物. 37.免疫グロブリンは,破傷風,百日咳,B型肝炎,Rho(D),水痘帯状疱 疹,および狂犬病に対する抗体からなる群より選択される「請求項35」記載の組 成物。 38.凝固製品は抗血友病VIII因子,IX因子複合体および活性化IX因子複合体か らなる群より選択される「請求項35」記載の組成物. 39.プロテアーゼ阻害剤はα−1プロテアーゼ阻害剤および抗トロンビンIII からなる群より選択される「請求項35」記載の組成物. 40.生物学的に活性な製品は,全血,血漿,血清,胎盤,乳汁,尿,細胞培養 物および細胞培養液上清からなる群より選択される生物学的起源から得られる「 請 求項33」記載の組成物. 41.生物学的起源は細胞培養物または細胞培養液上清であり,製品はコロニー 刺激因子,モノクローナル抗体およびそれらの誘導体,ならびに増殖因子からな る群より選択される「請求項40」記載の組成物. 42.生物学的起源は細胞培養物または細胞培養液上清あり,製品は組換え体で ある「請求項41」記載の組成物. 43.増殖因子はエリトロポエチン,サイトカインおよびインターロイキンから なる群より選択される「請求項41」記載の組成物. 44.生物学的に活性な製品は鎮痛剤である「請求項34」記載の組成物. 45.鎮痛剤はモルヒネ,ベンゾカイン,ペチジンおよびデメロールからなる群 より選択される「請求項44」記載の組成物. 46.生物学的に活性な製品は麻酔剤である「請求項34」記載の組成物. 47.麻酔剤はブピビカイン,アトラキュリウムおよびベキュロニウムからなる 群より選択される「請求項46」記載の組成物. 48.生物学的に活性な製品は化学療法剤である「請求項34」記載の組成物. 49.化学療法剤は放射性同位元素,ビンカアルカロイド,アドリアマイシン, 硫酸ブレオマイシン,カルボプラチン,シスプラチン,シクロホスファミド,シ タラビン,ダカルバジン,ダクチノマイシン,塩酸ドゥアノルビシン,塩酸ドキ ソルビシン,エトポシド,フルオロウラシル,塩酸メクロロレタミン,メルファ ラン,メルカプトプリン,メトトレキセート,マイトマイシン,マイトタン,ペ ントスタチン,ピポブロマン,塩酸プロカルベーズ,ストレプトゾトシン,タキ ソール,チオグアニン,ならびにウラシルマスタードからなる群より選択される 「請求項48」記載の組成物. 50.生物学的に活性な製品はホルモンである「請求項34」記載の組成物. 51.ホルモンはエストロジェン,テストステロン,プロゲステロンおよびそれ らの合成同族体からなる群より選択される「請求項50」記載の組成物. 52.生物学的に活性な製品はワクチンである「請求項34」記載の組成物. 53.ワクチンは,単一および多重抗原サブユニットワクチン.ならびに死菌お よび死ウイルスプレパレーションからなる群より選択される「請求項52」 記載の組成物. 54.乾燥したサンプルの残留水分含量は約4%未満である「請求項34」記載の 組成物. 55.残留水分含量は約2%未満である「請求項54」記載の組成物. 56.残留水分含量は約1%未満である「請求項55」記載の組成物. 57.脂質エンベローブをもたないウイルスはA型肝炎ウイルスおよびパルボウ イルスからなる群より選択される「請求項34」記載の組成物. 58.脂質エンベローブをもたないウイルスは,パルボウイルスである「請求項 57」記載の組成物.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/647,515 US6632648B1 (en) | 1996-05-14 | 1996-05-14 | Methods of terminal sterilization of fibrinogen |
US08/647,515 | 1996-05-14 | ||
PCT/GB1997/001317 WO1997042980A1 (en) | 1996-05-14 | 1997-05-14 | Methods of terminal sterilization of biological products |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000511519A true JP2000511519A (ja) | 2000-09-05 |
JP2000511519A5 JP2000511519A5 (ja) | 2004-12-09 |
JP4841018B2 JP4841018B2 (ja) | 2011-12-21 |
Family
ID=24597275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54066697A Expired - Lifetime JP4841018B2 (ja) | 1996-05-14 | 1997-05-14 | 生物学的製品の最終滅菌法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US6632648B1 (ja) |
EP (1) | EP0914166B1 (ja) |
JP (1) | JP4841018B2 (ja) |
AT (1) | ATE245455T1 (ja) |
AU (1) | AU730931B2 (ja) |
BR (1) | BR9709082A (ja) |
CA (1) | CA2254914C (ja) |
DE (1) | DE69723703T2 (ja) |
DK (1) | DK0914166T3 (ja) |
ES (1) | ES2202613T3 (ja) |
NZ (1) | NZ333212A (ja) |
PT (1) | PT914166E (ja) |
WO (1) | WO1997042980A1 (ja) |
ZA (1) | ZA974179B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009502876A (ja) * | 2005-07-29 | 2009-01-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 滅菌パンクレアチン粉末の製法 |
JP2009537163A (ja) * | 2006-05-22 | 2009-10-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | パンクレアチン試料中のウィルス負荷の分離及び決定するための方法 |
WO2013147299A1 (ja) * | 2012-03-31 | 2013-10-03 | 学校法人早稲田大学 | 生体組織の処理方法及び生体組織 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US6627426B2 (en) | 1997-02-14 | 2003-09-30 | Invitrogen Corporation | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
US6383810B2 (en) | 1997-02-14 | 2002-05-07 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
WO2000000225A1 (en) * | 1998-06-30 | 2000-01-06 | Invitrogen Corporation | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
BR9905867A (pt) * | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula |
CZ307715B6 (cs) | 1999-02-22 | 2019-03-06 | University Of Connecticut | Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu |
JP4493769B2 (ja) * | 1999-12-21 | 2010-06-30 | 旭化成ケミカルズ株式会社 | 球形顆粒 |
CA2442284C (en) * | 2001-04-04 | 2009-10-06 | Delsitech Oy | Biodegradable carrier and method for preparation thereof |
WO2005058207A1 (en) | 2003-12-11 | 2005-06-30 | Isto Technologies, Inc. | Particulate cartilage system |
ES2553457T3 (es) | 2004-05-27 | 2015-12-09 | Nanotherapeutics, Inc. | Inactivación de un patógeno en una muestra mediante un tratamiento con formalina y luz UV |
JP5133061B2 (ja) * | 2004-10-20 | 2013-01-30 | エシコン・インコーポレイテッド | 強化された吸収性複層の止血用創傷手当て用品および製造方法 |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
WO2007025290A2 (en) | 2005-08-26 | 2007-03-01 | Isto Technologies, Inc. | Implants and methods for repair, replacement and treatment of joint disease |
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
US8182840B2 (en) | 2005-09-27 | 2012-05-22 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US20090012629A1 (en) | 2007-04-12 | 2009-01-08 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
US20120177610A1 (en) * | 2007-09-19 | 2012-07-12 | Kieu Hoang | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins |
TR201900207T4 (tr) | 2008-11-07 | 2019-02-21 | Baxalta GmbH | Faktör VIII Formülasyonları |
US9827205B2 (en) * | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
EP2236617A1 (en) | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
WO2012009299A1 (en) * | 2010-07-13 | 2012-01-19 | Cephalon, Inc. | Improved methods for the sterilization of bendamustine |
WO2012170905A1 (en) | 2011-06-10 | 2012-12-13 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
CA3133869A1 (en) | 2011-08-26 | 2013-03-07 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
KR102196009B1 (ko) | 2011-10-25 | 2021-01-04 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
KR102236805B1 (ko) | 2012-07-11 | 2021-04-05 | 티슈테크, 인코포레이티드 | Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법 |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
TW201603818A (zh) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | 組成物及方法 |
US20160243288A1 (en) | 2015-02-23 | 2016-08-25 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
TWI720984B (zh) | 2015-05-20 | 2021-03-11 | 美商帝聖工業公司 | 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法 |
TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
IL310285A (en) | 2021-08-13 | 2024-03-01 | Biotest Ag | Fibrinogen preparations and preparation methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557717A (en) | 1968-05-17 | 1971-01-26 | Gen Mills Inc | Process for making candy floss |
US3619294A (en) | 1968-07-15 | 1971-11-09 | Penick & Ford Ltd | Method of combining crystalline sugar with impregnating agents and products produced thereby |
US3632357A (en) | 1969-07-29 | 1972-01-04 | Standard Brands Inc | Method of producing hard candy |
US3655442A (en) | 1969-08-27 | 1972-04-11 | California & Hawaiian Sugar | Method of making sugar and sugar products |
DE2246013A1 (de) | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
US4127502A (en) | 1977-06-10 | 1978-11-28 | Eastman Kodak Company | Stabilizers for reconstituted, lyophilized samples |
LU78955A1 (de) | 1978-01-27 | 1979-09-06 | Chimicasa Gmbh | Verfahren zur inaktivierung von viren |
US4158544A (en) | 1978-07-17 | 1979-06-19 | Beckman Instruments, Inc. | Process for preparing a biological composition for use as a reference control in diagnostic analysis |
US4588744A (en) | 1978-09-19 | 1986-05-13 | Mchugh John E | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide |
FR2442554A1 (fr) | 1978-11-24 | 1980-06-20 | Thomson Brandt | Commutateur electronique a commande tactile, et selecteur de canaux comportant un tel commutateur |
DE3176491D1 (en) * | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
US4440679A (en) * | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4294826A (en) | 1980-05-07 | 1981-10-13 | Armour Pharmaceutical Company | Process for the preparation of highly purified antihemophilic factor |
US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
JPS57140724A (en) | 1981-02-25 | 1982-08-31 | Green Cross Corp:The | Heat-treatment of aqueous solution containing cold insoluble globulin |
US4327077A (en) | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4879280A (en) | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
US4994438A (en) | 1981-11-02 | 1991-02-19 | Cedars Sinai Medical Center | Heat treatment of lyophilized plasma fractions |
US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
JPS58216695A (ja) | 1982-06-07 | 1983-12-16 | Otsuka Shokuhin Kogyo Kk | トレハロ−スの製造方法 |
US4883762A (en) | 1983-06-06 | 1989-11-28 | Ciba Corning Diagnostics Corp. | Stabilized isoenzyme control products |
US4865871A (en) | 1983-08-23 | 1989-09-12 | Board Of Regents The University Of Texas System | Method for cryopreparing biological tissue |
US4490361A (en) | 1983-12-02 | 1984-12-25 | Alpha Therapeutic Corporation | Virus inactivating heat treatment of plasma fractions |
AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
JPS60258195A (ja) | 1984-06-05 | 1985-12-20 | Ss Pharmaceut Co Ltd | α.α―トレハロース脂肪酸ジエステル誘導体 |
DE3434472A1 (de) | 1984-09-20 | 1986-03-27 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur pasteurisation von plasmaproteinen bzw. von plasmaproteinfraktionen |
DE3445010A1 (de) | 1984-12-10 | 1986-06-19 | Boehringer Mannheim Gmbh | Kontroll- bzw. eichserum fuer die lipid-diagnostik |
US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
GB8505882D0 (en) | 1985-03-07 | 1985-04-11 | Central Blood Lab Authority | Purification of blood coagulation factor viii |
GB8508173D0 (en) | 1985-03-28 | 1985-05-01 | Standard Telephones Cables Ltd | Controlled delivery device |
EP0229810B1 (en) | 1985-07-09 | 1991-10-16 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4758657A (en) | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
EP0212040B1 (de) | 1985-08-05 | 1990-05-23 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren |
CA1276563C (en) | 1985-09-30 | 1990-11-20 | Stanley E. Charm | High temperature, short time heating system and method of sterilizing heat-sensitive biological fluids |
EP0225581A3 (en) * | 1985-11-30 | 1989-05-24 | Green Cross Corporation | Method for the heat-treatment of immunoglobulins and immunoglobulin product |
JPS62174094A (ja) | 1985-12-16 | 1987-07-30 | Ss Pharmaceut Co Ltd | α.α―トレハロース誘導体 |
GB8604983D0 (en) | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
JPH0662436B2 (ja) | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
US4762857A (en) | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
US4749783A (en) | 1986-07-11 | 1988-06-07 | Miles Laboratories, Inc. | Viral inactivation and purification of active proteins |
FR2604157B1 (fr) | 1986-09-18 | 1989-09-01 | Air Liquide | Structure isotherme |
NL8700484A (nl) | 1987-02-26 | 1988-09-16 | Victor George Ryhiner | Vriesdroogkamer volgens een modulerende directe expansie principe. |
US5097018A (en) | 1988-05-12 | 1992-03-17 | University Of Southern California | Sequential heat treatment of blood-clotting factor products |
US5099002A (en) | 1987-05-15 | 1992-03-24 | University Of Southern California | Sequential improved method for treatment of human blood-clotting factor products |
US5118795A (en) * | 1987-05-15 | 1992-06-02 | University Of Southern California | Sequential heat treatment of blood-clotting factor products |
JP2545231B2 (ja) | 1987-06-18 | 1996-10-16 | 日本ケミカルリサ−チ株式会社 | ウロキナ−ゼの加熱による低分子化抑制法 |
GB8715238D0 (en) | 1987-06-29 | 1987-08-05 | Quadrant Bioresources Ltd | Food process |
US4909940A (en) | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
US5045446A (en) | 1988-08-26 | 1991-09-03 | Cryopharm Corporation | Lyophilization of cells |
WO1990011756A1 (en) | 1989-04-12 | 1990-10-18 | Aberdeen University | Slow release vitreous systems |
EP0399321B1 (en) | 1989-05-24 | 1993-06-23 | Miles Inc. | Gel filtration of heat treated factor viii |
GB8917470D0 (en) | 1989-07-31 | 1989-09-13 | Quadrant Bioresources Ltd | Composition and method |
US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
IT1246350B (it) | 1990-07-11 | 1994-11-17 | Eurand Int | Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili |
AU650678B2 (en) | 1990-08-10 | 1994-06-30 | Analytical Control Systems, Inc. | Stabilization (using gelatin from a cold water fish) of enzymes in diagnostic controls |
US5200399A (en) | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
CA2092995C (en) | 1991-07-31 | 2003-10-14 | Urs Maier | Grinder for grinding a cylindrical or spherical surface of a roll, especially a paper machine roll |
GB9125695D0 (en) | 1991-12-03 | 1992-01-29 | Mastavac Limited | Medical preparations |
DK0615438T3 (da) | 1991-12-05 | 1996-11-11 | Mallinckrodt Veterinary Inc | En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
IT1254359B (it) * | 1992-05-11 | 1995-09-14 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti il-6 |
JP3182564B2 (ja) | 1992-08-24 | 2001-07-03 | 味の素ファルマ株式会社 | 栄養組成物 |
US5422384A (en) | 1992-11-25 | 1995-06-06 | Battelle Memorial Institute | Glass/polymer composites and methods of making |
JP3168550B2 (ja) | 1992-12-02 | 2001-05-21 | 株式会社林原生物化学研究所 | 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品 |
RU2143889C1 (ru) | 1993-02-23 | 2000-01-10 | Генентек, Инк. | Способ стабилизации полипептида, способы получения композиций полипептида и композиции |
AU4953393A (en) | 1993-08-24 | 1995-03-21 | Mogen International N.V. | Production of trehalose in plants |
JP4142095B2 (ja) | 1994-06-02 | 2008-08-27 | クアドラント・ドラツグ・デリバリー・リミテツド | 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物 |
DE69532492T2 (de) | 1994-08-31 | 2004-12-02 | Mitsubishi Pharma Corp. | Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
JPH08157491A (ja) | 1994-11-30 | 1996-06-18 | Hayashibara Biochem Lab Inc | トレハロース誘導体の製造方法 |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE19528221C2 (de) * | 1995-08-01 | 1998-10-22 | Blutspendedienst Der Drk Lande | Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
-
1996
- 1996-05-14 US US08/647,515 patent/US6632648B1/en not_active Expired - Lifetime
-
1997
- 1997-05-14 ZA ZA9704179A patent/ZA974179B/xx unknown
- 1997-05-14 CA CA002254914A patent/CA2254914C/en not_active Expired - Lifetime
- 1997-05-14 JP JP54066697A patent/JP4841018B2/ja not_active Expired - Lifetime
- 1997-05-14 AU AU27845/97A patent/AU730931B2/en not_active Expired
- 1997-05-14 DE DE69723703T patent/DE69723703T2/de not_active Expired - Lifetime
- 1997-05-14 EP EP97921969A patent/EP0914166B1/en not_active Expired - Lifetime
- 1997-05-14 PT PT97921969T patent/PT914166E/pt unknown
- 1997-05-14 BR BR9709082-4A patent/BR9709082A/pt not_active Application Discontinuation
- 1997-05-14 DK DK97921969T patent/DK0914166T3/da active
- 1997-05-14 NZ NZ333212A patent/NZ333212A/xx unknown
- 1997-05-14 WO PCT/GB1997/001317 patent/WO1997042980A1/en active IP Right Grant
- 1997-05-14 AT AT97921969T patent/ATE245455T1/de active
- 1997-05-14 ES ES97921969T patent/ES2202613T3/es not_active Expired - Lifetime
-
2003
- 2003-06-04 US US10/455,284 patent/US20030211592A1/en not_active Abandoned
-
2007
- 2007-02-20 US US11/709,006 patent/US20070249033A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009502876A (ja) * | 2005-07-29 | 2009-01-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 滅菌パンクレアチン粉末の製法 |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
JP2009537163A (ja) * | 2006-05-22 | 2009-10-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | パンクレアチン試料中のウィルス負荷の分離及び決定するための方法 |
WO2013147299A1 (ja) * | 2012-03-31 | 2013-10-03 | 学校法人早稲田大学 | 生体組織の処理方法及び生体組織 |
US10660977B2 (en) | 2012-03-31 | 2020-05-26 | Waseda University | Method for treating biological tissue and biological tissue |
Also Published As
Publication number | Publication date |
---|---|
WO1997042980A1 (en) | 1997-11-20 |
EP0914166B1 (en) | 2003-07-23 |
PT914166E (pt) | 2003-12-31 |
DE69723703D1 (de) | 2003-08-28 |
ATE245455T1 (de) | 2003-08-15 |
ZA974179B (en) | 1997-12-10 |
JP4841018B2 (ja) | 2011-12-21 |
AU730931B2 (en) | 2001-03-22 |
US20030211592A1 (en) | 2003-11-13 |
ES2202613T3 (es) | 2004-04-01 |
US20070249033A1 (en) | 2007-10-25 |
NZ333212A (en) | 2000-05-26 |
AU2784597A (en) | 1997-12-05 |
EP0914166A1 (en) | 1999-05-12 |
DE69723703T2 (de) | 2004-01-29 |
CA2254914C (en) | 2008-07-29 |
DK0914166T3 (da) | 2003-11-10 |
US6632648B1 (en) | 2003-10-14 |
BR9709082A (pt) | 2001-11-27 |
CA2254914A1 (en) | 1997-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4841018B2 (ja) | 生物学的製品の最終滅菌法 | |
US5118794A (en) | Process for stabilizing human albumin solutions and the solution obtained | |
US5019495A (en) | Tissue culture antiviral processes and compositions | |
CA2034489C (en) | Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions | |
JP4278861B2 (ja) | ウイルス汚染に対する安全性の高いフィブリンのり形成用成分をヒト血漿プールから製造する方法 | |
AU2003237391B2 (en) | Sterilization, stabilization and preservation of functional biologics | |
EP0050061A2 (en) | Method of reducing undesirable activities of biological and pharmaceutical products | |
Ng et al. | Pasteurization of antihemophilic factor and model virus inactivation studies | |
JPH029367A (ja) | 感染性物質の不活性化法 | |
CN101757651A (zh) | 一种动物纤维蛋白原病毒灭活方法 | |
US20110104298A1 (en) | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma | |
JP4629831B2 (ja) | ウィルスの不活化方法 | |
JPH09187273A (ja) | タンパク質中のウイルスを不活性化する方法 | |
AU2007205748B2 (en) | Sterilization, stabilization and preservation of functional biologics | |
US20110251127A1 (en) | Inactivation of infectious agents in plasma proteins by extreme pressure | |
MXPA98009535A (en) | Methods for the terminal sterilization of biologi products | |
SOUZANGARZADEH et al. | Inactivation of poliovirus type-1 and HSV-1 in human coagulation factor VII concentrate by pasteurization | |
US20210292740A1 (en) | Methods for viral inactivation of human platelet lysate | |
CN1225020A (zh) | 生物制品的终末灭菌 | |
Allersma et al. | Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis | |
Sofer | Part 3a, Plasma and Plasma Products | |
KR20050020971A (ko) | 기능성 생물제제의 멸균, 안정화 및 보존 방법 | |
IE55182B1 (en) | Heat treatment of plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040419 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071211 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080325 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080924 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081030 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090528 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110518 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110620 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110715 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111004 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141014 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |